<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245037</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00000210</org_study_id>
    <secondary_id>P30CA016058</secondary_id>
    <secondary_id>OHSU-HEM-05011-L</secondary_id>
    <secondary_id>OHSU-210</secondary_id>
    <nct_id>NCT00245037</nct_id>
  </id_info>
  <brief_title>Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer</brief_title>
  <acronym>Bu Flu TBI</acronym>
  <official_title>A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor
      peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops
      the patient's immune system from rejecting the donor's stem cells. The donated stem cells may
      replace the patient's immune system and help destroy any remaining cancer cells
      (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte
      infusion) after the transplant may help increase this effect. Sometimes the transplanted
      cells from a donor can also make an immune response against the body's normal cells. Giving
      cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.

      PURPOSE: This phase I/II trial is studying the side effects of giving busulfan and
      fludarabine together with total-body irradiation and to see how well they work in treating
      patients who are undergoing a donor stem cell transplant for hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess safety and toxicity of the addition of busulfan added to an established
           fludarabine and low-dose total-body irradiation (TBI) conditioning regimen for
           non-myeloablative allogeneic transplantation in patients with hematologic malignancies.
           (Phase I)

        -  To assess the non-relapse mortality 1-year after conditioning with busulfan and
           fludarabine/TBI in patients with hematologic malignancies at moderate to high risk for
           graft rejection and/or relapse of underlying disease. (Phase II)

      Secondary

        -  To assess overall survival 1-year survival. (Phase II)

        -  To assess the incidence of graft rejection. (Phase II)

        -  To assess the incidence of grade II-IV acute graft-vs-host disease (GVHD) and chronic
           extensive GVHD. (Phase II)

        -  To assess rates of disease progression and/or relapse-related mortality. (Phase II)

        -  To determine non-hematologic grade III-IV organ specific toxicity. (Phase II)

      OUTLINE:

        -  Nonmyeloablative-conditioning regimen: Patients receive busulfan IV on day -5 and
           fludarabine IV over 30 minutes on days -4 to -2. Patients undergo total body irradiation
           on day 0.

        -  Allogeneic peripheral blood stem cell transplantation (PBSC): Patients undergo donor
           PBSC infusion on day 0.

        -  Graft-versus-host disease prophylaxis: Patients receive oral cyclosporine twice daily on
           days -3 to 56 followed by a taper to day 180. Patients with a related stem cell donor
           receive oral mycophenolate mofetil twice daily on days 0-28. Patients with an unrelated
           stem cell donor receive oral mycophenolate mofetil 3 times daily on days 0-28 followed
           by a taper twice daily to day 56. Patients with evidence of relapse or persistent
           disease may also receive up to 3 donor lymphocyte infusions.

      PROJECTED ACCRUAL: A total of 225 patients will be accrued for this study; 25 patients
      accrued into the Phase I and 200 patients into Phase II.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regimen-Related Toxicities</measure>
    <time_frame>5 years post-transplant</time_frame>
    <description>Non-hematologic toxicities and adverse experiences ≥ Grade 3 occurrences measured up to day +100 using the NCI Common Toxicity Criteria for Adverse Events v3.0 (CTCAE). Infections and GVHD will be assessed up to 5 years post transplant. The following data represents the number of regimen-related, grade 3 and 4 toxicities that occurred in each category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>Two years post-transplant</time_frame>
    <description>Percent of subjects with non-relapse mortality two years after conditioning with busulfan with fludarabine/200 cGy TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Years 1, 2, 3 and 5</time_frame>
    <description>The percentage of overall patient survival (out of 147 participants) for Years 1, 2, 3 and 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Years 1, 2, 3, and 5</time_frame>
    <description>The percentage of progression-free patients (out of 147 participants) at Years 1, 2, 3, and 5.
Definition of Disease Progression:
MM/Plasma Cell: Increasing bone pain or increase in serum/urine monoclonal protein by 25%.
CLL/NHL/HD: New sites of lymphadenopathy; ≥ 25% increase in lymph node size; Blood or bone marrow involvement with clonal B-cells; Increase of ≥ 25% bone marrow involvement; ≥ 25% increase in blood involvement with clonal B-cells.
AML/ALL: Any incidence of relapse (&gt;5% blasts) by evaluation of the bone marrow aspirate.
CML: Inability to control platelet or granulocyte counts; Increase in baseline number of metaphases demonstrating the Ph+ chromosome by &gt;25%; Any other new cytogenetic abnormality; Transformation to accelerated phase or blast crisis.
MDS/MPD: Any evidence by morphologic or flow cytometric evaluation of the bone marrow aspirate of new blasts (&gt;5%) or worsening cytopenia or cytogenetic evidence of recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Mortality</measure>
    <time_frame>Years 1 and 2</time_frame>
    <description>The percentage of patients (out of 147 participants) who relapsed at Years 1 and 2. Relapse is defined as the presence of &gt;5% blasts by morphology on a post-transplant bone marrow aspirate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft-Versus-Host Disease (aGVHD) Outcome</measure>
    <time_frame>Day 100, Month 6</time_frame>
    <description>Grading of Acute GVHD:
Severity of Individual Organ Involvement:
Skin
1 a maculopapular eruption involving less than 25% of the body surface
2 a maculopapular eruption involving 25-50% of the body surface
3 generalized erythroderma
4 generalized erythroderma with bullous formation and/or with desquamation Liver
1 bilirubin 2.0-3.0mg/100mL
2 bilirubin 3-5.9mg/100mL
3 bilirubin 6-14.9mg/100mL
4 bilirubin &gt;15mg/100mL Gut Diarrhea is graded +1 to +4 in severity. Nausea/vomiting and/or anorexia caused by GVHD is assigned as +1 in severity Diarrhea
1 &lt;1000mL of liquid stool/day
2 &gt;1,000mL of stool/day
3 &gt;1,500mL of stool/day
4 2,000mL of stool/day, severe abdominal pain, with or without ileus
Severity of GVHD:
Grade 1 +1 to +2 skin rash; No gut or liver involvement Grade 2 +1 to +3 skin rash;+1 GI involvement and/or +1 liver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft-Versus-Host Disease (cGVHD) Outcome</measure>
    <time_frame>Years 1, 2 and 3</time_frame>
    <description>Grading of Chronic GVHD:
Limited: Localized skin involvement and/or hepatic dysfunction due to chronic GVHD
Extensive:
One or more of the following:
Generalized skin involvement Liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis Involvement of the eye: Schirmer's test with &lt;5 mm wetting Involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy Involvement of any other target organ
Chronic GVHD Severity:
Mild: Signs and symptoms of cGVHD do not interfere substantially with function and do not progress once appropriately treated with local therapy or standard systemic therapy.
Moderate: Signs and symptoms of cGVHD interfere somewhat with function despite appropriate therapy or are progressive through first line systemic therapy.
Severe: Signs and symptoms of cGVHD limit function substantially despite appropriate therapy or are progressive through second line systemic therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <description>A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.</description>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV busulfan is available and diluted and administered per package insert guidelines.</description>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).
- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d.</description>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.
Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.
Monitoring: Fludarabine level is not monitored.
Dose Adjustments: There are no provisions for fludarabine dose adjustments.</description>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.
Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).
Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).</description>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:
In autologous transplants, patients receive their own stem cells.
In syngeneic transplants, patients receive stem cells from their identical twin.
In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used.</description>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation (TBI)</intervention_name>
    <description>TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.
Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.
Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min.</description>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte colony-stimulating factor (G-CSF)</intervention_name>
    <description>Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).
It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.
Toxicities: At the dosage used, the most common side effect will be medullary bone pain.
Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all).</description>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenytoin</intervention_name>
    <description>This drug is used to prevent seizures while on chemotherapy.</description>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.</description>
    <arm_group_label>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of a hematologic malignancy of 1 of the following high-risk types:

               -  Acute lymphoblastic leukemia

               -  Acute myeloid leukemia

               -  Chronic myelogenous leukemia

               -  Chronic lymphocytic leukemia

               -  Myelodysplastic syndromes

               -  Myeloproliferative disorder

               -  Multiple myeloma

               -  Plasma cell dyscrasias

               -  Non-Hodgkin lymphoma

               -  Hodgkin disease

        PATIENT CHARACTERISTICS:

        Performance status

          -  Karnofsky 50-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  No liver failure

          -  No cirrhosis with evidence of portal hypertension

          -  No alcoholic hepatitis

          -  No esophageal varices

          -  No chronic hepatitis

          -  No other liver disease

        Renal

          -  Not specified

        Cardiovascular

          -  Left Ventricular Ejection Fraction (LVEF) &gt; 35%

          -  No symptomatic coronary artery disease or cardiac failure requiring therapy

        Pulmonary

          -  Diffusing capacity of lung for carbon monoxide (DLCO) &gt; 30%

          -  Total lung capacity &gt; 30%

          -  Forced expiratory volume in 1 second (FEV_1) &gt; 30%

          -  No supplementary continuous oxygen

        Other

          -  HIV negative

          -  No active nonhematologic malignancy except localized skin cancer

          -  No overt organ dysfunction

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Maziarz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <results_first_submitted>April 20, 2017</results_first_submitted>
  <results_first_submitted_qc>May 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2017</results_first_posted>
  <disposition_first_submitted>November 28, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>November 28, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 29, 2016</disposition_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Richard Maziarz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia, breakpoint cluster region-Abelson (BCR-ABL) negative</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Phenytoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</title>
          <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130">17 participants died from infectious complications.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</title>
          <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Score (KPS)</title>
          <description>KPS Scale:
100 = Normal, no complaints, no evidence of disease. 90 = Able to carry on normal activity; minor signs or symptoms of disease. 80 = Normal activity with effort; some signs or symptoms of disease. 70 = Cares for self, unable to carry on normal activity or to do active work. 60 = Requires occasional assistance, but is able to care for most of his/her needs.
50 = Requires considerable assistance and frequent medical care. 40-0 = Not eligible</description>
          <population>Eight patients did not have KPS status available, which is why the values do not add up to the total number of participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="139"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>KPS ≥ 90</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>KPS &lt; 90</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-Transplant Disease Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>In Complete Remission</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not in Complete Remission</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Risk Index (DRI)</title>
          <population>DRI was unclassifiable in 3 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Low or intermediate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High or Very High</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HLA Match</title>
          <description>HLA Criteria:
Related to the patient and genotypically or phenotypically HLA-identical (8/8). Single antigen mismatch (7/8) can be accepted if no other donor is available.
OR
Unrelated to the patient and HLA matched by molecular typing, allowing a single allele or antigen mismatch (7/8).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>8/8</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7/8</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Relation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Related Sibling Donor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unrelated Donor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cytomegalovirus (CMV) Status</title>
          <population>Cytomegalovirus (CMV) status was unavailable in 7 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>-/- recipient/donor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>All other combinations</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor/Recipient Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>F/F, M/M, M/F</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>F/M</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Regimen-Related Toxicities</title>
        <description>Non-hematologic toxicities and adverse experiences ≥ Grade 3 occurrences measured up to day +100 using the NCI Common Toxicity Criteria for Adverse Events v3.0 (CTCAE). Infections and GVHD will be assessed up to 5 years post transplant. The following data represents the number of regimen-related, grade 3 and 4 toxicities that occurred in each category.</description>
        <time_frame>5 years post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</title>
            <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including</description>
          </group>
        </group_list>
        <measure>
          <title>Regimen-Related Toxicities</title>
          <description>Non-hematologic toxicities and adverse experiences ≥ Grade 3 occurrences measured up to day +100 using the NCI Common Toxicity Criteria for Adverse Events v3.0 (CTCAE). Infections and GVHD will be assessed up to 5 years post transplant. The following data represents the number of regimen-related, grade 3 and 4 toxicities that occurred in each category.</description>
          <units>Toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CNS Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-relapse Mortality</title>
        <description>Percent of subjects with non-relapse mortality two years after conditioning with busulfan with fludarabine/200 cGy TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease.</description>
        <time_frame>Two years post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</title>
            <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality</title>
          <description>Percent of subjects with non-relapse mortality two years after conditioning with busulfan with fludarabine/200 cGy TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The percentage of overall patient survival (out of 147 participants) for Years 1, 2, 3 and 5.</description>
        <time_frame>Years 1, 2, 3 and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</title>
            <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The percentage of overall patient survival (out of 147 participants) for Years 1, 2, 3 and 5.</description>
          <units>percentage of analyzed participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival</title>
        <description>The percentage of progression-free patients (out of 147 participants) at Years 1, 2, 3, and 5.
Definition of Disease Progression:
MM/Plasma Cell: Increasing bone pain or increase in serum/urine monoclonal protein by 25%.
CLL/NHL/HD: New sites of lymphadenopathy; ≥ 25% increase in lymph node size; Blood or bone marrow involvement with clonal B-cells; Increase of ≥ 25% bone marrow involvement; ≥ 25% increase in blood involvement with clonal B-cells.
AML/ALL: Any incidence of relapse (&gt;5% blasts) by evaluation of the bone marrow aspirate.
CML: Inability to control platelet or granulocyte counts; Increase in baseline number of metaphases demonstrating the Ph+ chromosome by &gt;25%; Any other new cytogenetic abnormality; Transformation to accelerated phase or blast crisis.
MDS/MPD: Any evidence by morphologic or flow cytometric evaluation of the bone marrow aspirate of new blasts (&gt;5%) or worsening cytopenia or cytogenetic evidence of recurrence.</description>
        <time_frame>Years 1, 2, 3, and 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</title>
            <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival</title>
          <description>The percentage of progression-free patients (out of 147 participants) at Years 1, 2, 3, and 5.
Definition of Disease Progression:
MM/Plasma Cell: Increasing bone pain or increase in serum/urine monoclonal protein by 25%.
CLL/NHL/HD: New sites of lymphadenopathy; ≥ 25% increase in lymph node size; Blood or bone marrow involvement with clonal B-cells; Increase of ≥ 25% bone marrow involvement; ≥ 25% increase in blood involvement with clonal B-cells.
AML/ALL: Any incidence of relapse (&gt;5% blasts) by evaluation of the bone marrow aspirate.
CML: Inability to control platelet or granulocyte counts; Increase in baseline number of metaphases demonstrating the Ph+ chromosome by &gt;25%; Any other new cytogenetic abnormality; Transformation to accelerated phase or blast crisis.
MDS/MPD: Any evidence by morphologic or flow cytometric evaluation of the bone marrow aspirate of new blasts (&gt;5%) or worsening cytopenia or cytogenetic evidence of recurrence.</description>
          <units>percentage of analyzed participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Mortality</title>
        <description>The percentage of patients (out of 147 participants) who relapsed at Years 1 and 2. Relapse is defined as the presence of &gt;5% blasts by morphology on a post-transplant bone marrow aspirate.</description>
        <time_frame>Years 1 and 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</title>
            <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Mortality</title>
          <description>The percentage of patients (out of 147 participants) who relapsed at Years 1 and 2. Relapse is defined as the presence of &gt;5% blasts by morphology on a post-transplant bone marrow aspirate.</description>
          <units>percentage of analyzed participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft-Versus-Host Disease (aGVHD) Outcome</title>
        <description>Grading of Acute GVHD:
Severity of Individual Organ Involvement:
Skin
1 a maculopapular eruption involving less than 25% of the body surface
2 a maculopapular eruption involving 25-50% of the body surface
3 generalized erythroderma
4 generalized erythroderma with bullous formation and/or with desquamation Liver
1 bilirubin 2.0-3.0mg/100mL
2 bilirubin 3-5.9mg/100mL
3 bilirubin 6-14.9mg/100mL
4 bilirubin &gt;15mg/100mL Gut Diarrhea is graded +1 to +4 in severity. Nausea/vomiting and/or anorexia caused by GVHD is assigned as +1 in severity Diarrhea
1 &lt;1000mL of liquid stool/day
2 &gt;1,000mL of stool/day
3 &gt;1,500mL of stool/day
4 2,000mL of stool/day, severe abdominal pain, with or without ileus
Severity of GVHD:
Grade 1 +1 to +2 skin rash; No gut or liver involvement Grade 2 +1 to +3 skin rash;+1 GI involvement and/or +1 liver</description>
        <time_frame>Day 100, Month 6</time_frame>
        <population>This is cumulative incidence of grades 2-4 aGVHD at 100 days and at 6 months. Out of the total number of participants, grades 2-4 aGVHD occurred in 79 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</title>
            <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft-Versus-Host Disease (aGVHD) Outcome</title>
          <description>Grading of Acute GVHD:
Severity of Individual Organ Involvement:
Skin
1 a maculopapular eruption involving less than 25% of the body surface
2 a maculopapular eruption involving 25-50% of the body surface
3 generalized erythroderma
4 generalized erythroderma with bullous formation and/or with desquamation Liver
1 bilirubin 2.0-3.0mg/100mL
2 bilirubin 3-5.9mg/100mL
3 bilirubin 6-14.9mg/100mL
4 bilirubin &gt;15mg/100mL Gut Diarrhea is graded +1 to +4 in severity. Nausea/vomiting and/or anorexia caused by GVHD is assigned as +1 in severity Diarrhea
1 &lt;1000mL of liquid stool/day
2 &gt;1,000mL of stool/day
3 &gt;1,500mL of stool/day
4 2,000mL of stool/day, severe abdominal pain, with or without ileus
Severity of GVHD:
Grade 1 +1 to +2 skin rash; No gut or liver involvement Grade 2 +1 to +3 skin rash;+1 GI involvement and/or +1 liver</description>
          <population>This is cumulative incidence of grades 2-4 aGVHD at 100 days and at 6 months. Out of the total number of participants, grades 2-4 aGVHD occurred in 79 patients.</population>
          <units>percentage of analyzed participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Graft-Versus-Host Disease (cGVHD) Outcome</title>
        <description>Grading of Chronic GVHD:
Limited: Localized skin involvement and/or hepatic dysfunction due to chronic GVHD
Extensive:
One or more of the following:
Generalized skin involvement Liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis Involvement of the eye: Schirmer’s test with &lt;5 mm wetting Involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy Involvement of any other target organ
Chronic GVHD Severity:
Mild: Signs and symptoms of cGVHD do not interfere substantially with function and do not progress once appropriately treated with local therapy or standard systemic therapy.
Moderate: Signs and symptoms of cGVHD interfere somewhat with function despite appropriate therapy or are progressive through first line systemic therapy.
Severe: Signs and symptoms of cGVHD limit function substantially despite appropriate therapy or are progressive through second line systemic therapy</description>
        <time_frame>Years 1, 2 and 3</time_frame>
        <population>This is a cumulative incidence of cGVHD at 1 year, 2 years, and 3 years. A total of 99 patients (out of 147) developed cGVHD, 86 patients (87%) with extensive stage cGVHD and 13 patients (13%) with limited stage cGVHD.</population>
        <group_list>
          <group group_id="O1">
            <title>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</title>
            <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Graft-Versus-Host Disease (cGVHD) Outcome</title>
          <description>Grading of Chronic GVHD:
Limited: Localized skin involvement and/or hepatic dysfunction due to chronic GVHD
Extensive:
One or more of the following:
Generalized skin involvement Liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis Involvement of the eye: Schirmer’s test with &lt;5 mm wetting Involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy Involvement of any other target organ
Chronic GVHD Severity:
Mild: Signs and symptoms of cGVHD do not interfere substantially with function and do not progress once appropriately treated with local therapy or standard systemic therapy.
Moderate: Signs and symptoms of cGVHD interfere somewhat with function despite appropriate therapy or are progressive through first line systemic therapy.
Severe: Signs and symptoms of cGVHD limit function substantially despite appropriate therapy or are progressive through second line systemic therapy</description>
          <population>This is a cumulative incidence of cGVHD at 1 year, 2 years, and 3 years. A total of 99 patients (out of 147) developed cGVHD, 86 patients (87%) with extensive stage cGVHD and 13 patients (13%) with limited stage cGVHD.</population>
          <units>percentage of analyzed participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-hematologic toxicities and adverse experiences ≥ Grade 3 will be assessed up to day +100 using the NCI Common Toxicity Criteria for Adverse Events v3.0 (CTCAE). Infections and GVHD will be assessed up to 5 years post transplant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)</title>
          <description>Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV Busulfan is available and diluted and administered per package insert guidelines.
Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation/flutter</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Respiratory pulseless electrical activity (PEA) arrest</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Iron overload</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Steroid myopathy</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>ABO incompatability</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Thrombosis/deep vein thrombosis</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura (TTP)</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Refractory ascites</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Ogilvie’s syndrome</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-occlusive disease</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Death Caused by Bacterial Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to regimen</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Death Caused by Fungal Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to regimen</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Death Caused by Sepsis/Septic Shock</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to regimen</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Death Caused by Viral Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to regimen</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Death Caused by Nonspecified Pneumonia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Unrelated to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fractures/musculoskeletal</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CsA toxicity</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Posterior-reversible encephalopathy syndrome</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Event associated with CsA</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptogenic organizing pneumonia</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Eosinophilic pneumonia</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia or transaminitis</sub_title>
                <description>Related to regimen</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <description>Unrelated to Regimen</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard T. Maziarz, MD</name_or_title>
      <organization>Oregon Health and Science University</organization>
      <phone>503-494-6345</phone>
      <email>maziarzr@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

